Ke Hao
Impact in
-
- Cancer-related molecular mechanisms research
- Cancer, Lipids, and Metabolism
-
- Ferroptosis and cancer prognosis
Papers in
-
- Wnt/β-catenin signaling in development and cancer 2
- PI3K/AKT/mTOR signaling in cancer 2
-
- Cancer Mechanisms and Therapy 5
- Co-authors
- Kaiqiang Li (19 shared papers)Zhen Wang (13 shared papers)Bingyu Chen (11 shared papers)Kaixuan Li (2 shared papers)Wanli Jiang (1 shared paper)Wei Yang (1 shared paper)Zhen Wang (1 shared paper)Rongrong Hao (1 shared paper)
In The Last Decade
Ke Hao
29 papers receiving 380 citations
Peers
Comparison fields: 5 of 78
- Cancer Research 65
- Pulmonary and Respiratory Medicine 93
- Pharmaceutical Science 18
- Biomaterials 38
- Immunology 47
Countries citing papers authored by Ke Hao
This map shows the geographic impact of Ke Hao's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ke Hao with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ke Hao more than expected).
Fields of papers citing papers by Ke Hao
This network shows the impact of papers produced by Ke Hao. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ke Hao. The network helps show where Ke Hao may publish in the future.
Co-authors
The 25 scholars most cited alongside Ke Hao, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 32 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | 2022 | 102 | |
| 2 | 2020 | 34 | |
| 3 | 2024 | 31 | |
| 4 | 2016 | 26 | |
| 5 | 2018 | 22 | |
| 6 | 2017 | 21 | |
| 7 | 2020 | 20 | |
| 8 | 2016 | 16 | |
| 9 | 2023 | 14 | |
| 10 | 2021 | 13 | |
| 11 | 2017 | 10 | |
| 12 | 2020 | 10 | |
| 13 | 2021 | 9 | |
| 14 | 2017 | 7 | |
| 15 | 2017 | 7 | |
| 16 | 2017 | 7 | |
| 17 | 2018 | 5 | |
| 18 | 2018 | 5 | |
| 19 | 2020 | 5 | |
| 20 | 2023 | 4 |
About Ke Hao
Ke Hao is a scholar working on Molecular Biology, Pathology and Forensic Medicine, Biomaterials, Cell Biology and Pulmonary and Respiratory Medicine, having authored 32 papers that have together received 384 indexed citations. Recurring topics across this work include Cancer Mechanisms and Therapy (5 papers), Phytochemistry and Bioactive Compounds (5 papers), Liver physiology and pathology (2 papers), Wnt/β-catenin signaling in development and cancer (2 papers), PI3K/AKT/mTOR signaling in cancer (2 papers), Photonic and Optical Devices (2 papers), Caveolin-1 and cellular processes (2 papers) and Lung Cancer Treatments and Mutations (2 papers). The work is most often cited by research in Cancer Research (65 citations), Pulmonary and Respiratory Medicine (93 citations), Pharmaceutical Science (18 citations), Biomaterials (38 citations) and Immunology (47 citations). Ke Hao has collaborated with scholars based in China, Vietnam and Nigeria. Frequent co-authors include Kaiqiang Li, Zhen Wang, Bingyu Chen, Kaixuan Li, Wanli Jiang, Wei Yang, Zhen Wang, Rongrong Hao, Bin Lü and Chunyan Dai. Their work appears in journals such as Journal of Zhejiang University SCIENCE B, Oncotarget, Biochemical and Biophysical Research Communications, Scientific Reports and ACS Applied Materials & Interfaces.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.